In vitro cytotoxic and genotoxic evaluation of peptides used in nuclear medicine (DOTATATE and Ubiquicidin29-41) in CHO-K1 cells

Micronucleus (MN) assay constitutes a valuable surrogate to the chromosome aberration technique for in vitro testing of the genotoxicity of substances. As test substances, two peptidic compounds (DOTATATE and Ubiquicidin 29-41 ) used in nuclear medicine, were tested for in vitro cytotoxicity and gen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cytotechnology (Dordrecht) 2016-12, Vol.68 (6), p.2301-2310
Hauptverfasser: Ocampo, Ivette Zegarra, de Queiroz Souza Passos, Priscila, Ramirez de Carvalho, Luma, Lira da Cruz, Camila Ayala, Esteves-Pedro, Natália Mencacci, Medeiros da Silva, Fabiana, Higa, Olga Zazuco, Dias, Luiz Alberto Pereira, Okazaki, Kayo, Vieira, Daniel Perez
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Micronucleus (MN) assay constitutes a valuable surrogate to the chromosome aberration technique for in vitro testing of the genotoxicity of substances. As test substances, two peptidic compounds (DOTATATE and Ubiquicidin 29-41 ) used in nuclear medicine, were tested for in vitro cytotoxicity and genotoxicity in CHO-K1 cells. None of the compounds showed detectable cytotoxicity (0.5–7.3 ng/mL for DOTATATE and 0.3–4.5 ng/mL for UBI 29-41 ), genotoxicity (0.72, 7.2 and 72.0 ng/ml for DOTATATE and 0.45, 4.5 and 45.0 ng/mL for UBI 29-41 ) or cell cycle changes as compared to untreated controls at the concentrations tested. Statistical analysis showed good concordance between two independent analysts. The results corroborate the notion of the safety of the compounds and present improvements of the in vitro MN assay when performed in a pre-clinical trial context that increase the throughput of small-to-medium testing facilities as an alternative to high content screening systems.
ISSN:0920-9069
1573-0778
DOI:10.1007/s10616-016-0024-9